SOUTH SAN FRANCISCO, Calif., April 21 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that it will release results for the first quarter of 2006 after close of the stock market on Wednesday, May 3, 2006.
Company management will also host a conference call at 2:00 p.m. PDT on May 3 to discuss first quarter 2006 results. The dial-in number for domestic callers will be (800) 309-2906 and for international callers will be (706) 634-0903. The conference ID number is 8127798.
To listen to the live webcast of the conference call please go to www.cotherix.com and click on the “Investor Relations” link. There will be a replay available for approximately two weeks following the call. The conference call, replay and webcast are open to all interested parties.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix’s Ventavis(R) (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms (World Health Organization Group I). PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix, the CoTherix logo and REVEAL Registry are trademarks of CoTherix, Inc. Ventavis is a registered trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com
CoTherix, Inc.
CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551
Web site: http://www.cotherix.com//
